Evidence-based guideline: Treatment of painful diabetic neuropathy—report of the american association of neuromuscular and electrodiagnostic medicine, the american academy of neurology, and the american academy of physical medicine & rehabilitation
dc.contributor.author | Bril, Vera | en_US |
dc.contributor.author | England, John D. | en_US |
dc.contributor.author | Franklin, Gary M. | en_US |
dc.contributor.author | Backonja, Miroslav | en_US |
dc.contributor.author | Cohen, Jeffrey A. | en_US |
dc.contributor.author | Del Toro, David R. | en_US |
dc.contributor.author | Feldman, Eva L. | en_US |
dc.contributor.author | Iverson, Donald J. | en_US |
dc.contributor.author | Perkins, Bruce | en_US |
dc.contributor.author | Russell, James W. | en_US |
dc.contributor.author | Zochodne, Douglas W. | en_US |
dc.date.accessioned | 2011-06-10T14:21:35Z | |
dc.date.available | 2012-07-12T17:42:23Z | en_US |
dc.date.issued | 2011-06 | en_US |
dc.identifier.citation | Bril, Vera; England, John D.; Franklin, Gary M.; Backonja, Miroslav; Cohen, Jeffrey A.; Del Toro, David R.; Feldman, Eva L.; Iverson, Donald J.; Perkins, Bruce; Russell, James W.; Zochodne, Douglas W. (2011). "Evidence-based guideline: Treatment of painful diabetic neuropathy—report of the american association of neuromuscular and electrodiagnostic medicine, the american academy of neurology, and the american academy of physical medicine & rehabilitation." Muscle & Nerve 43(6): 910-917. <http://hdl.handle.net/2027.42/84412> | en_US |
dc.identifier.issn | 0148-639X | en_US |
dc.identifier.issn | 1097-4598 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/84412 | |
dc.description.abstract | The objective of this report was to develop a scientifically sound and clinically relevant evidence-based guideline for the treatment of painful diabetic neuropathy (PDN). The basic question that was asked was: “What is the efficacy of a given treatment (pharmacological: anticonvulsants, antidepressants, opioids, others; non-pharmacological: electrical stimulation, magnetic field treatment, low-intensity laser treatment, Reiki massage, others) to reduce pain and improve physical function and quality of life (QOL) in patients with PDN?” A systematic review of literature from 1960 to August 2008 was performed, and studies were classified according to the American Academy of Neurology classification of evidence scheme for a therapeutic article. Recommendations were linked to the strength of the evidence. The results indicate that pregabalin is established as effective and should be offered for relief of PDN (Level A). Venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, opioids (morphine sulfate, tramadol, and oxycodone controlled-release), and capsaicin are probably effective and should be considered for treatment of PDN (Level B). Other treatments have less robust evidence, or the evidence is negative. Effective treatments for PDN are available, but many have side effects that limit their usefulness. Few studies have sufficient information on their effects on function and QOL. Muscle Nerve, 2011. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Neuroscience, Neurology and Psychiatry | en_US |
dc.title | Evidence-based guideline: Treatment of painful diabetic neuropathy—report of the american association of neuromuscular and electrodiagnostic medicine, the american academy of neurology, and the american academy of physical medicine & rehabilitation | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Neurosciences | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | University Health Network, University of Toronto, Toronto, Ontario, Canada ; AANEM, 2621 Superior Drive NW, Rochester, MN 55901 | en_US |
dc.contributor.affiliationother | Department of Neurology, Louisiana State University School of Medicine, New Orleans, Louisiana, USA | en_US |
dc.contributor.affiliationother | University of Washington, Seattle, Washington, USA | en_US |
dc.contributor.affiliationother | University of Wisconsin, Madison, Wisconsin, USA | en_US |
dc.contributor.affiliationother | Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA | en_US |
dc.contributor.affiliationother | Department of Physical Medicine and Rehabilitation, Medical College of Wisconsin, Milwaukee, Wisconsin, USA | en_US |
dc.contributor.affiliationother | Humboldt Neurological Medical Group, Inc., Eureka, California, USA | en_US |
dc.contributor.affiliationother | University Health Network, University of Toronto, Toronto, Ontario, Canada | en_US |
dc.contributor.affiliationother | Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA ; Disclaimer: This report is provided as an education service of the AANEM, the AAN, and the AAMP&R. It is based on an assessment of current scientific and clinical information. It is not intended to include all possible proper methods of care for a particular neurological problem or all legitimate criteria for choosing to use a specific procedure. Neither is it intended to exclude any reasonable alternative methodologies. The AANEM, AAN, and AAPM&R recognize that specific care decisions are the prerogative of the patient and physician caring for the patient, based on all of the circumstances involved. Disclosures: V.B. has received research support from Talecris, Eisai, and Johnson & Johnson. J.D.E. has received honoraria from Talecris for consulting work and speaking; holds financial interests in Pfizer; and has received research support from Wyeth, the NIH, Astra Zeneca, and Pfizer. M.B. is on the editorial boards of Pain , Journal of Pain , Clinical Journal of Pain , European Journal of Pain , and Pain Medicine ; he provided consultation to and holds corporate appointments with Allergan, Astellas, J&J, Lilly, Merck, Neurogesx, and Pfizer, and conducted clinical research with Neurogesx. J.A.C. has received funding for travel from the National ALS Association; has received honoraria from a neurology practice in Massachusetts; serves on the speakers' bureau of Athena Diagnostics; and has given expert testimony, prepared an affidavit, and acted as a witness in a legal proceeding with regard to vaccine-related injuries and peripheral nerve injuries. E.L.F. has served as a journal editor for the Journal of the Peripheral Nervous System , Endocrinology , and Neurobiology of Disease ; has received royalties from UpToDate; has received honoraria from the Neurological Institute of New York, the Detroit Medical Center, and the University of Pennsylvania; is on the Data Safety Monitoring Board of Novartis; and receives research support from the NIH. D.J.I. has been a treating expert witness with regard to a legal proceeding. J.W.R. has received financial compensation from Exelexis Corp. and Baxter Corp.; has received honoraria from the AAN and several hospitals and academic institutions; and has received research support from Baxter Corporation, the NIH, the VA, the American Diabetes Association, and the Juvenile Diabetes Association. D.W.Z. serves on the advisory board for Aegera, Inc.; has received honoraria from ONO, Japan; and holds stock options in and receives research support from Aegera. | en_US |
dc.contributor.affiliationother | University of Calgary, Calgary, Alberta, Canada | en_US |
dc.identifier.pmid | 21484835 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/84412/1/22092_ftp.pdf | |
dc.identifier.doi | 10.1002/mus.22092 | en_US |
dc.identifier.source | Muscle & Nerve | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.